397 related articles for article (PubMed ID: 25850708)
1. Prospective Randomized Trial Comparing Efficacy of Topical Loteprednol Etabonate 0.5% Versus Cyclosporine-A 0.05% for Treatment of Dry Eye Syndrome Following Hematopoietic Stem Cell Transplantation.
Boynton GE; Raoof D; Niziol LM; Hussain M; Mian SI
Cornea; 2015 Jul; 34(7):725-32. PubMed ID: 25850708
[TBL] [Abstract][Full Text] [Related]
2. Effect of loteprednol etabonate 0.5% on initiation of dry eye treatment with topical cyclosporine 0.05%.
Sheppard JD; Donnenfeld ED; Holland EJ; Slonim CB; Solomon R; Solomon KD; McDonald MB; Perry HD; Lane SS; Pflugfelder SC; Samudre SS
Eye Contact Lens; 2014 Sep; 40(5):289-96. PubMed ID: 25083776
[TBL] [Abstract][Full Text] [Related]
3. Safety and efficacy of cyclosporine 0.05% drops versus unpreserved artificial tears in dry-eye patients having laser in situ keratomileusis.
Salib GM; McDonald MB; Smolek M
J Cataract Refract Surg; 2006 May; 32(5):772-8. PubMed ID: 16765793
[TBL] [Abstract][Full Text] [Related]
4. Loteprednol Etabonate for the Treatment of Dry Eye Disease.
Beckman K; Katz J; Majmudar P; Rostov A
J Ocul Pharmacol Ther; 2020 Sep; 36(7):497-511. PubMed ID: 32391735
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of topical cyclosporine 0.05% in the treatment of dry eye associated with graft versus host disease.
Rao SN; Rao RD
Cornea; 2006 Jul; 25(6):674-8. PubMed ID: 17077659
[TBL] [Abstract][Full Text] [Related]
6. Treatment of ocular graft-versus-host disease with topical cyclosporine 0.05%.
Malta JB; Soong HK; Shtein RM; Musch DC; Rhoades W; Sugar A; Mian SI
Cornea; 2010 Dec; 29(12):1392-6. PubMed ID: 20847658
[TBL] [Abstract][Full Text] [Related]
7. The effect of decreasing the dosage of cyclosporine A 0.05% on dry eye disease after 1 year of twice-daily therapy.
Su MY; Perry HD; Barsam A; Perry AR; Donnenfeld ED; Wittpenn JR; D'Aversa G
Cornea; 2011 Oct; 30(10):1098-104. PubMed ID: 21407074
[TBL] [Abstract][Full Text] [Related]
8. Effects of topical cyclosporine a plus artificial tears versus artificial tears treatment on conjunctival goblet cell density in dysfunctional tear syndrome.
Demiryay E; Yaylali V; Cetin EN; Yildirim C
Eye Contact Lens; 2011 Sep; 37(5):312-5. PubMed ID: 21792057
[TBL] [Abstract][Full Text] [Related]
9. Topical cyclosporine-A in dry eye associated with chronic graft versus host disease.
Kurt RA; Yalçindag N; Atilla H; Arat M
Ann Ophthalmol (Skokie); 2009; 41(3-4):166-9. PubMed ID: 20214049
[TBL] [Abstract][Full Text] [Related]
10. [Study on the treatment of dry eye with Loteprednol Etabonate].
Wan PX; Wang XR; Song YY; Li ZY; Duan HC; Zhang W; Liu Z; Wang ZC
Zhonghua Yan Ke Za Zhi; 2012 Feb; 48(2):142-7. PubMed ID: 22490950
[TBL] [Abstract][Full Text] [Related]
11. Corneal and conjunctival sensitivity in patients with dry eye: the effect of topical cyclosporine therapy.
Toker E; Asfuroğlu E
Cornea; 2010 Feb; 29(2):133-40. PubMed ID: 19966564
[TBL] [Abstract][Full Text] [Related]
12. Comparison of prednisolone acetate and loteprednol etabonate for the treatment of benzalkonium chloride-induced dry eye syndrome in rats.
Beyazyıldız E; Acar U; Beyazyıldız Ö; Pınarlı FA; Albayrak A; Uğurlu N; Tiryaki M; Delibaşi T
J Ocul Pharmacol Ther; 2014 May; 30(4):306-12. PubMed ID: 24494746
[TBL] [Abstract][Full Text] [Related]
13. Effects of corneal nerve density on the response to treatment in dry eye disease.
Kheirkhah A; Dohlman TH; Amparo F; Arnoldner MA; Jamali A; Hamrah P; Dana R
Ophthalmology; 2015 Apr; 122(4):662-8. PubMed ID: 25542519
[TBL] [Abstract][Full Text] [Related]
14. Loteprednol Etabonate 0.5% Gel Vs. Prednisolone Acetate 1% Solution After Descemet Membrane Endothelial Keratoplasty: Prospective Randomized Trial.
Price MO; Feng MT; Scanameo A; Price FW
Cornea; 2015 Aug; 34(8):853-8. PubMed ID: 26020827
[TBL] [Abstract][Full Text] [Related]
15. Topical loteprednol pretreatment reduces cyclosporine stinging in chronic dry eye disease.
Sheppard JD; Scoper SV; Samudre S
J Ocul Pharmacol Ther; 2011 Feb; 27(1):23-7. PubMed ID: 21133792
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of topical cyclosporine for the treatment of dry eye disease.
Perry HD; Solomon R; Donnenfeld ED; Perry AR; Wittpenn JR; Greenman HE; Savage HE
Arch Ophthalmol; 2008 Aug; 126(8):1046-50. PubMed ID: 18695097
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of topical cyclosporine A in the treatment of severe trachomatous dry eye.
Guzey M; Karaman SK; Satici A; Ozardali I; Sezer S; Bozkurt O
Clin Exp Ophthalmol; 2009 Aug; 37(6):541-9. PubMed ID: 19702702
[TBL] [Abstract][Full Text] [Related]
18. Reduced Efficacy of Low-dose Topical Steroids in Dry Eye Disease Associated With Graft-versus-Host Disease.
Yin J; Kheirkhah A; Dohlman T; Saboo U; Dana R
Am J Ophthalmol; 2018 Jun; 190():17-23. PubMed ID: 29572107
[TBL] [Abstract][Full Text] [Related]
19. Phase III safety evaluation of cyclosporine 0.1% ophthalmic emulsion administered twice daily to dry eye disease patients for up to 3 years.
Barber LD; Pflugfelder SC; Tauber J; Foulks GN
Ophthalmology; 2005 Oct; 112(10):1790-4. PubMed ID: 16102833
[TBL] [Abstract][Full Text] [Related]
20. Topical Cyclosporine Pretreatment of Ocular Surface in Allogeneic Hematopoietic Stem Cell Transplant Recipients.
Chun YH; Beak JU; Kim HS; Na KS
J Ocul Pharmacol Ther; 2018 Nov; 34(9):628-632. PubMed ID: 30289329
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]